Latest Blog Posts Tagged "Industry"
Uncovering the Promise of c-Abl as a Therapeutic Target: Testing Available Treatments and Supporting New Therapies
March 15, 2017
MJFF CEO Todd Sherer, PhD, discusses varied work happening around c-Abl inhibitors, an emerging therapeutic target that has shown early promise as a potential disease-modifying therapy.
February 10, 2017
MJFF funded early research of this novel drug candidate, mGluR4, helping remove financial and other barriers to advance its testing.
January 10, 2017
The FDA recently agreed to review the New Drug Application for a dyskinesia medication developed by Adamas Pharmaceuticals.
August 25, 2016
With confidence from MJFF-led studies, Denali Therapeutics today announced it has licensed LRRK2 inhibitor compounds from Genentech.
August 24, 2016
To keep you informed of the Foundation's research investments, we're highlighting a few newly funded grants supporting the development of therapies to address common non-motor symptoms of Parkinson's.
July 12, 2016
Today MJFF, the Van Andel Research Institute and the Cure Parkinson's Trust announced plans to collaborate to assess the clinical use and development of cancer drug nilotinib.
March 29, 2016
An FDA advisory committee voted 12-2 in favor of approval of Nuplazid, a drug for Parkinson's disease psychosis. The agency will make its decision by May 1, 2016.
January 13, 2014
Alpha-synuclein — the protein that clumps in the cells of Parkinson's patients — is a target for disease-modifying therapies. Read about four promising research projects targeting alpha-synuclein....
November 27, 2013
Constipation causes great discomfort in Parkinson's disease patients and can decrease the body's ability to absorb medicine used to treat the disease.
September 06, 2012
The deadline for academic and industry researchers to apply to the Therapeutics Pipeline Program is this coming Wednesday, September 12.